TY - JOUR
T1 - Buprenorphine and methadone treatment for opioid dependence by income, ethnicity and race of neighborhoods in New York City
AU - Hansen, Helena
AU - Siegel, Carole
AU - Wanderling, Joseph
AU - DiRocco, Danae
N1 - Funding Information:
We gratefully acknowledge the assistance of Dawn Lambert-Wacey of the New York State Office of Alcoholism and Substance Abuse for her help accessing the methadone usage data for this study, as well as the New York State Bureau of Narcotics for assistance in accessing buprenorphine usage data. Thanks also to the thoughtful feedback of three anonymous reviewers, and to Sonia Mendoza and Jennifer Hernandez for copy editing. This study was supported by NIH award DA032674-05 (to Hansen), the Robert Wood Johnson Foundation Health Policy Investigator Award (to Hansen), the New York University Department of Psychiatry statistical analysis unit, and the New York State Office of Mental Health Center of Excellence in Culturally Competent Mental Health.
Funding Information:
This work was supported by NIH DA032674 (to the first author), and by the Robert Wood Johnson Health Policy Investigator Award Program (to the first author). Additional support was granted by the Nathan Kline Institute's Center of Excellence in Culturally Competent Mental Health, funded by the New York State Office of Mental Health .
Publisher Copyright:
© 2016.
PY - 2016/7/1
Y1 - 2016/7/1
N2 - Background: Geographic and demographic variation in buprenorphine and methadone treatment use in U.S. cities has not been assessed. Identifying variance in opioid maintenance is essential to improving treatment access and equity. Purpose: To examine the differential uptake of buprenorphine treatment in comparison to methadone treatment between 2004 and 2013 in neighborhoods in New York City characterized by income, race and ethnicity. Methods: Social area (SA) analysis of residential zip codes of methadone and buprenorphine patients in NYC, which aggregated zip codes into five social areas with similar percentages of residents below poverty, identifying as Black non-Hispanic and as Hispanic, to examine whether treatment rates differed significantly among social areas over time. For each rate, mixed model analyses of variance were run with fixed effects for social area, year and the interaction of social area by year. Results: Buprenorphine treatment increased in all social areas over time with a significantly higher rate of increase in the social area with the highest income and the lowest percentage of Black, Hispanic, and low-income residents. Methadone treatment decreased slightly in all social areas until 2011 and then increased bringing rates back to 2004 levels. Treatment patterns varied by social area. Conclusions: Buprenorphine treatment rates are increasing in all social areas, with slower uptake in moderate income mixed ethnicity areas. Methadone rates have remained stable over time. Targeted investments to promote public sector buprenorphine prescription may be necessary to reduce disparities in buprenorphine treatment and to realize its potential as a public health measure.
AB - Background: Geographic and demographic variation in buprenorphine and methadone treatment use in U.S. cities has not been assessed. Identifying variance in opioid maintenance is essential to improving treatment access and equity. Purpose: To examine the differential uptake of buprenorphine treatment in comparison to methadone treatment between 2004 and 2013 in neighborhoods in New York City characterized by income, race and ethnicity. Methods: Social area (SA) analysis of residential zip codes of methadone and buprenorphine patients in NYC, which aggregated zip codes into five social areas with similar percentages of residents below poverty, identifying as Black non-Hispanic and as Hispanic, to examine whether treatment rates differed significantly among social areas over time. For each rate, mixed model analyses of variance were run with fixed effects for social area, year and the interaction of social area by year. Results: Buprenorphine treatment increased in all social areas over time with a significantly higher rate of increase in the social area with the highest income and the lowest percentage of Black, Hispanic, and low-income residents. Methadone treatment decreased slightly in all social areas until 2011 and then increased bringing rates back to 2004 levels. Treatment patterns varied by social area. Conclusions: Buprenorphine treatment rates are increasing in all social areas, with slower uptake in moderate income mixed ethnicity areas. Methadone rates have remained stable over time. Targeted investments to promote public sector buprenorphine prescription may be necessary to reduce disparities in buprenorphine treatment and to realize its potential as a public health measure.
KW - Buprenorphine
KW - Methadone
KW - Racial disparities
KW - Treatment disparities
UR - http://www.scopus.com/inward/record.url?scp=84969913349&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84969913349&partnerID=8YFLogxK
U2 - 10.1016/j.drugalcdep.2016.03.028
DO - 10.1016/j.drugalcdep.2016.03.028
M3 - Article
C2 - 27179822
AN - SCOPUS:84969913349
SN - 0376-8716
VL - 164
SP - 14
EP - 21
JO - Drug and alcohol dependence
JF - Drug and alcohol dependence
ER -